XYLT2 Antibody (N-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q9H1B5 |
---|---|
Clone Names | 100318278 |
Gene ID | 64132 |
---|---|
Other Names | Xylosyltransferase 2, Peptide O-xylosyltransferase 1, Xylosyltransferase II, XT-II, XylT-II, XYLT2, XT2 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | XYLT2 |
---|---|
Synonyms | XT2 |
Function | Catalyzes the first step in the biosynthesis of chondroitin sulfate, heparan sulfate and dermatan sulfate proteoglycans, such as DCN. Transfers D-xylose from UDP-D-xylose to specific serine residues of the core protein. |
Cellular Location | Golgi apparatus membrane; Single- pass type II membrane protein. Secreted |
Tissue Location | Widely expressed. Expressed at higher level in kidney and pancreas. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The protein encoded by this gene is an isoform ofxylosyltransferase, which belongs to a family ofglycosyltransferases. This enzyme transfers xylose from UDP-xyloseto specific serine residues of the core protein and initiates thebiosynthesis of glycosaminoglycan chains in proteoglycans includingchondroitin sulfate, heparan sulfate, heparin and dermatan sulfate.The enzyme activity, which is increased in scleroderma patients, isa diagnostic marker for the determination of sclerotic activity insystemic sclerosis.
References
Condac, E., et al. Glycobiology 19(8):829-833(2009)Casanova, J.C., et al. Biochem. Biophys. Res. Commun. 383(1):4-10(2009)Ponighaus, C., et al. Am. J. Hypertens. 22(4):432-436(2009)Ambrosius, M., et al. Clin. Biochem. 42 (1-2), 1-4 (2009) :Hendig, D., et al. Clin. Chim. Acta 398 (1-2), 90-94 (2008) :
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.